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Abstract
Aims/hypothesis We investigated the direct effect of a nitric
oxide donor (spermine NONOate) on glucose transport in
isolated human skeletal muscle and L6 skeletal muscle cells.
We hypothesised that pharmacological treatment of human
skeletalmusclewith N-(2-aminoethyl)-N-(2-hydroxy-2-nitro-
sohydrazino)-1,2-ethylenediamine (spermine NONOate)
would increase intracellular cyclic GMP (cGMP) levels and
promote glucose transport.
Methods Skeletal muscle strips were prepared from vastus
lateralis muscle biopsies obtained from seven healthy men.
Muscle strips were incubated in the absence or presence of
5 mmol/l spermine NONOate or 120 nmol/l insulin. The L6
muscle cells were treated with spermine NONOate
(20 µmol/l) and incubated in the absence or presence of
insulin (120 nmol/l). The direct effect of spermine NON-
Oate and insulin on glucose transport, cGMP levels and
signal transduction was determined.
Results In human skeletal muscle, spermine NONOate
increased glucose transport 2.4-fold (p<0.05), concomitant
with increased cGMP levels (80-fold, p<0.001). Phosphor-
ylation of components of the canonical insulin signalling
cascade was unaltered by spermine NONOate exposure,
implicating an insulin-independent signalling mechanism.
Consistent with this, spermine NONOate increased AMP-
activated protein kinase (AMPK)-α1-associated activity
(1.7-fold, p<0.05). In L6 muscle cells, spermine NONOate
increased glucose uptake (p<0.01) and glycogen synthesis
(p<0.001), an effect that was in addition to that of insulin.
Spermine NONOate also elicited a concomitant increase in
AMPK and acetyl-CoA carboxylase phosphorylation. In the
presence of the guanylate cyclase inhibitor LY-83583
(10 µmol/l), spermine NONOate had no effect on glycogen
synthesis and AMPK-α1 phosphorylation.
Conclusions/interpretation Pharmacological treatment of
skeletal muscle with spermine NONOate increases glucose
transport via insulin-independent signalling pathways involv-
ing increased intracellular cGMP levels and AMPK-α1-
associated activity.
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GSK Glycogen synthase kinase
KHB Krebs–Henseleit buffer
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binding protein
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2-nitrosohydrazino)-1,2-
ethylenediamine
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Introduction
Nitric oxide is implicated in a wide array of signalling
networks [1]. In rodents and humans, exercise increases
skeletal muscle nitric oxide production, concomitant with
increased glucose uptake [2–4]. Nitric oxide biogenesis is
catalysed by different isoforms of nitric oxide synthase
(NOS) [5], of which neuronal-type NOS and endothelial-
type NOS isoforms are produced in skeletal muscle [1].
Neuronal-type NOS is produced at higher levels in human
skeletal muscle than brain [6] and therefore is likely to be
the major isoform involved in the effect of nitric oxide on
glucose metabolism [1]. Acute administration of the NOS
inhibitor NG-monomethyl-L-arginine during exercise in
humans reduces leg muscle glucose uptake [4], implicating
nitric oxide signalling in the mechanism by which exercise
controls glucose homeostasis.
The intracellular mechanism by which nitric oxide
increases skeletal muscle glucose uptake in humans is
incompletely resolved. Intra-femoral artery infusion of a
nitric oxide donor increased glucose uptake in healthy
participants [7], as well as in type 2 diabetic patients [8].
Furthermore, exposure of isolated rat skeletal muscle to the
nitric oxide donor sodium nitroprusside increased glucose
transport in a dose-dependent manner [9, 10]. Stimulation
of glucose transport by nitric oxide involves the activation
of a calcium/contraction- and phosphatidylinositol-3-
kinase-independent pathway that acutely increases GLUT4
content at the cell surface [11]. Nitric oxide seems to exert
its action on muscle glucose transport partly via activation
of guanylate cyclase, leading to elevation of cyclic GMP
(cGMP) levels [10, 12]. Indeed, the cGMP analogue 8-
bromo-cGMP also increases glucose uptake in isolated rat
skeletal muscle [10]. Thus, nitric oxide/cGMP signalling
may be part of a novel pathway that regulates skeletal
muscle glucose uptake.
The effect of exercise on the acute regulation of skeletal
muscle glucose transport has been attributed to several
signalling nodes including Ca
2+-calmodulin-dependent pro-
tein kinase (CaMK)II, AMP-activated protein kinase
(AMPK) and nitric oxide [13]. In this regard, the interaction
between AMPK and nitric oxide signalling pathways is
especially intriguing. AMPK is a serine/threonine protein
kinase, which acts as a sensor of cellular energy status and
regulates a wide variety of gene regulatory and metabolic
pathways, including glucose uptake and fatty acid oxidation
in skeletal muscle [14]. AMPK subunits (α1, α2, β1, β2,
γ1, γ2, γ3) form a heterotrimeric enzyme consisting of α
(catalytic), and β and γ (regulatory) isoforms. In rodent
skeletal muscle, sodium nitroprusside increases glucose
transport, concomitant with α1-associated AMPK activa-
tion [15]. Moreover, chronic exposure of L6 muscle cells to
sodium nitroprusside increases Glut4 (also known as
SLC2A4) mRNA expression by an AMPK-dependent
mechanism [16], positioning AMPK downstream of nitric
oxide signalling. AMPK is also considered to be an
upstream kinase for NOS, since it phosphorylates and
activates endothelial and neuronal NOS [17–19]. Thus, a
positive feedback interaction between AMPK and NOS in
the control of skeletal muscle metabolism is implicated
[16].
In the present study, we determined the effect of the
nitric oxide donor spermine N-(2-aminoethyl)-N-(2-hy-
droxy-2-nitrosohydrazino)-1,2-ethylenediamine NONOate
on glucose transport and intracellular signalling in isolated
human skeletal muscle. Using L6 skeletal muscle cells, we
also determined whether spermine NONOate and insulin
have additive effects on glucose uptake and intracellular
signalling. We hypothesised that pharmacological treatment
of human skeletal muscle with a compound that increases
cGMP levels may promote glucose uptake.
Methods
Study participants The study protocol was approved by the
regional Ethics Committee at Karolinska Institutet. In-
formed consent was received from all participants (n=7)
before participation. The clinical characteristics of the
healthy male volunteers are presented in Table 1. Glucose,
insulin and HbA1c values were within the normal range,
with no elevation of serum aminotransferase levels. None
of the participants used tobacco products or reported taking
any medication. The participants were asked to refrain from
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the laboratory after an overnight fast.
Muscle biopsy procedure Skeletal muscle (∼1g )w a s
obtained by means of an open biopsy. Biopsies were taken
under local anaesthesia (mepivakain chloride 5 mg/ml)
from the vastus lateralis portion of the quadriceps femoris
muscle [20]. An incision (∼4 cm) was made 15 cm above
the proximal border of patella and the muscle fascia was
exposed. Thereafter, four to five muscle fibre bundles were
excised and placed in oxygenated Krebs–Henseleit buffer
(KHB), which contained 5 mmol/l glucose, 15 mmol/
l mannitol and 0.1% (wt/vol.) BSA (RIA Grade; Sigma, St
Louis, MO, USA).
Muscle incubation procedure Smaller skeletal muscle strips
were dissected from the biopsy specimen, mounted on
Plexiglass clamps (9 mm in width) and incubated in vitro in
pregassed (95% O2 and 5% CO2) KHB in a shaking water
bath at 35°C for 30 min. The gas phase in the vials was
maintained during the incubation procedure. Thereafter,
skeletal muscle strips were incubated for 30 min at 35°C in
KHB in the absence (basal) or presence of either
5 mmol/l spermine NONOate (Calbiochem, San Diego,
CA, USA) or 120 nmol/l insulin (Insulin Actrapid; Novo
Nordisk, Bagsværd, Denmark). The concentrations of
spermine NONOate and insulin were maintained through-
out all remaining incubation procedures.
Glucose transport Skeletal muscle strips were transferred
to fresh KHB containing 20 mmol/l mannitol and incubated
at 35°C for 10 min. Thereafter, muscles were incubated for
20 min in KHB containing 5 mmol/l 3-O-methyl [
3H]
glucose (29.6 MBq/mmol) and 15 mmol/l [
14C]mannitol
(2.0 MBq/mmol). Thus, muscle strips were exposed to
either spermine NONOate or insulin for a total of 60 min.
At the end of the incubation protocol, skeletal muscle
specimens were blotted of excess fluid, snap-frozen in
liquid nitrogen and stored at −80°C until further analysis.
Glucose transport was determined by the accumulation of
intracellular 3-O-methyl-[
3H]glucose as previously de-
scribed [21].
Cyclic guanosine monophosphate measurement Skeletal
muscle strips were incubated in the absence or presence
of spermine NONOate as described above for 60 min and
then rapidly clamp frozen in liquid N2 cooled tongs. Frozen
muscles were homogenised on ice in 1 ml 10% (vol./vol.)
trichloroacetic acid using a polytron. Homogenates were
subjected to centrifugation for 10 min at 14,000 g.
Thereafter, the trichloroacetic acid was extracted from the
supernatant fraction with
2H2O-saturated diethyl ether.
Samples were then immediately frozen in liquid N2 and
concentrated in a speed vacuum. The concentrated samples
were resuspended in assay buffer and acetylated, after
which cGMP levels were measured by immunoassay
according to manufacturer’s instructions (cGMP BioTRAK,
RPN 226; Amersham, Pittsburgh, PA, USA). cGMP is
expressed as pmol/g wet weight.
AMP kinase activity Muscles were homogenised in ice-cold
lysis buffer containing 50 mmol/l Tris–HCl (pH 7.5),
1 mmol/l EDTA, 1 mmol/l dithiothreitol, 10% (vol./vol.)
glycerol, 50 mmol/l NaF, 5 mmol/l Na pyrophosphate,
1 mmol/l benzamidine, 0.1 mmol/l phenylmethyl sulfonyl
fluoride and 1% (vol./vol.) Triton X-100. Muscle homoge-
nates were subjected to centrifugation for 10 min at
14,000 g and 4°C. Supernatant fractions were removed
and used to determine protein content using a commercially
available kit based on the Bradford method (Bio-Rad,
Hercules, CA, USA). Aliquots (200 μg protein) were
incubated overnight at 4°C with antibodies against α1-
and α2-AMPK subunits (provided by D. G. Hardie,
Division of Molecular Physiology, College of Life Sciences,
University of Dundee, Dundee, UK). Human muscle
lysates from rested and exercised conditions were also
incubated overnight at 4°C with antibodies against the
AMPK-α1- and α2-subunits, and were used as positive
control for the assay. The immunoprecipitates were
washed once in lysis buffer, once in 480 mmol/l HEPES
(pH 7.0) and 240 mmol/l NaCl, and twice in 240 mmol/
l HEPES (pH 7.0) and 120 mmol/l NaCl, leaving 10 µl of
buffer with the Sepharose after the last wash. To determine
isoform-specific AMPK activity, the immunoprecipitates
Table 1 Clinical characteristics of the study participants
Characteristics Mean ± SE
Age (year) 50.1±3.8
Weight (kg) 78.6±2.5
Height (cm) 178.6±2.4
BMI (kg/m
2) 24.8±0.88
Insulin (pmol/l) 30±7.3
Plasma glucose (mmol/l) 5.2±0.2
HbA1c (%) 4.4±0.1
Total cholesterol (mmol/l) 4.9±0.24
HDL (mmol/l) 1.5±0.1
LDL (mmol/l) 3.4±0.2
Triacylglycerol (mmol/l) 1.0±0.3
ASAT (μkat/l) 0.40±0.04
ALAT (μkat/l) 0.41±0.05
γ-GT (μkat/l) 0.48±0.19
Results are presented as mean ± SEM for n=7 participants
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase;
γ-GT, gamma-glutamyltransferase
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containing 833 µmol/l diothiothreitol, 200 µmol/l AMP,
100 µmol/l AMARA-peptide (Upstate Millipore, Billerica,
MA, USA), 5 mmol/l MgCl2, 200 µmol/l ATP and 74 kBq
of [γ-
32P ] A T P .T h er e a c t i o nw a ss t o p p e db ys p o t t i n g2 5µ l
on to a piece of P81 filter paper, which was then washed four
times at 15 min per time in 1% (vol./vol.) phosphoric acid.
The dried filter paper was analysed for activity using liquid
scintillation counting.
Cell culture L6 muscle cells (provided by A. Klip, The
Hospital for Sick Children, Toronto, ON, Canada) were
grown in αMEM supplemented with 10% (vol./vol.) FBS,
1% (vol./vol.) penicillin and streptomycin (100 U/ml
penicillin, 100 µg/ml streptomycin), and 1% (vol./vol.)
fungizone in 5% CO2 95% O2 humidified air at 37°C. The
L6 cells were differentiated into myotubes for 6 days in
αMEM supplemented with 2% (vol./vol.) FBS. Myotubes
were then serum-starved for 3 h before the start of the
experiment. Myotubes were incubated under basal con-
ditions or in the presence or absence of spermine NONOate
(20 µmol/l) or a guanylate cyclase inhibitor (10 µmol/l LY-
83583) and glucose incorporation into glycogen (glycogen
synthesis), glucose uptake and protein signalling were
determined. To establish insulin-stimulated conditions,
insulin (120 nmol/l) was added during the last 20 min for
protein phosphorylation and glucose uptake analysis or
during the last 120 min for glycogen synthesis analysis.
Glucose incorporation to glycogen (glycogen synthesis)
Glycogen synthesis was assessed in L6 cells by measuring
the incorporation of D-[U-
14C]glucose into glycogen as
described [22]. Overnight serum-starved myotubes were
incubated in 6 well plates and treated for 1 h with spermine
NONOate (20 µmol/l) and LY-83583 (10 µmol/l), in the
absence or presence of insulin (120 nmol/l). During the last
90 min, the cells were incubated with medium supple-
mented with glucose (5 mmol/l) and D-[U-
14C]glucose
(final specific activity, 37 kBq/ml). Each experiment was
performed on duplicate wells. Glucose uptake and incor-
poration to glycogen was determined as mmol glucose per
mg protein per h.
Glucose uptake Myotubes were serum-starved for 3 to 5 h
and incubated with or without spermine NONOate
(20 µmol/l) in the absence or presence of insulin
(120 nmol/l). 2-Deoxyglucose uptake was determined as
described [23]. Each experiment was performed on dupli-
cate wells.
Western blot analysis A portion of the muscle specimen
incubated for the glucose transport assay was homogenised in
0.3 ml ice-cold lysis buffer using a glass-on-glass system with a
motor pestle. The buffer conta i n e d2 0m m o l / lT r i s( p H8 . 0 ) ,
137 mmol/l NaCl, 2.7 mmol/l KCl, 10 mmol/l NaF, 1 mmol/l
MgCl2, 1 mmol/l Na3VO4, 0.2 mmol/l phenylmethylsulfonyl
fluoride, 10% (wt/vol.) glycerol, 1% (wt/vol.) Triton X-100,
1 µg/ml aprotinin, 1 µg/ml leupeptin and 1 μmol/l microcystin.
L6 myotubes were collected into similar ice-cold lysis buffer.
Homogenates were solubilised by end-over-end mixing for
60 min at 4°C and subjected to centrifugation (for 10 min at
4°C and 12,000 g). The supernatant fraction was stored at
−80°C until use. Total protein was determined using a
commercially available kit (Pierce, Rockford, IL, USA). Equal
amounts of protein (40 µg) were diluted in Laemmli sample
buffer. Proteins were separated by SDS–PAGE and transferred
to membranes (Immobilon-P; Millipore). Phosphorylation and
levels of several proteins were determined using the following
antibodies: phospho-AMPK Thr
172, phospho-Akt Ser
473,
phospho-Akt-substrate (PAS), phospho-glycogen synthase
kinase (GSK)-α/β (Ser
21/9) and phospho-CaMKII Thr
286 (all
from Cell Signaling Technology, MA, USA), phospho-ACCβ
Ser
227 and ACC (Upstate Biotechnologies, MA, USA) and
GLUT4 (Chemicon, CA, USA). Anti-α1-AMPK and anti α2-
AMPK antibodies used for the immunoblot analysis were
kindly provided by D. G. Hardie (Division of Molecular
Physiology, College of Life Sciences, University of Dundee,
UK). All membranes were normalised for loading with
glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) or respective total protein
content. Proteins were visualised by chemiluminescence and
quantified by densitometry.
Statistics Data are reported as mean ± SE. Differences were
determined using a paired t test or ANOVA as appropriate.
Bonferroni test was used for post hoc analysis. Significance
was established at p<0.05.
Results
Effects of spermine NONOate on glucose transport and
AMP kinase activity We determined the effects of spermine
NONOate and insulin on glucose transport in intact human
skeletal muscle (Fig. 1a). Muscle strips were incubated in
the absence or presence of either 5 mmol/l spermine
NONOate or 120 nmol/l insulin and 3-O-methyl-glucose
transport was assessed. Insulin increased glucose transport
fivefold (p<0.05) in isolated skeletal muscle strips, consis-
tent with our earlier studies [24]. Spermine NONOate
increased skeletal muscle glucose transport 2.4-fold (p<
0.05), concomitant with increased cGMP levels (p<0.001)
(Fig. 1b). AMPK activation has been implicated in the
mechanism by which nitric oxide enhances glucose uptake
in skeletal muscle [15]. Thus, we determined the effects of
Diabetologia (2010) 53:1142–1150 1145spermine NONOate exposure on α-isoform-specific AMPK
signalling (Fig. 1c, d). For perspective, acute exercise
increased AMPK-α1- and AMPK-α2-associated activity in
skeletal muscle from healthy men by two- and 6.2-fold,
respectively vs rested conditions (Fig. 1e, f). Spermine
NONOate increased AMPK-α1-associated activity 1.7-fold
(p<0.05), while AMPK-α2-associated activity was un-
changed in isolated skeletal muscle. Previous studies from
our laboratory provide evidence that insulin does not alter
AMPK-α1- or AMPK-α2-associated activity in isolated
human skeletal muscle [25].
Effects of spermine NONOate on protein content and signal
transduction The effects of insulin or spermine NONOate
on canonical insulin signalling were determined in isolated
skeletal muscle using phospho-specific antibodies (Fig. 2a).
Exposure of human skeletal muscle to insulin increased the
phosphorylation of Akt (Ser
473), Tre-2/BUB2/CDC16
domain-containing protein family, member 1, domain
family 1/domain family 4 (pTBC1D1/D4) (detected using
a PAS antibody) and GSK3α/β (Ser
21/9), while spermine
NONOate had no effect (Fig. 2a–d). Neither insulin nor
spermine NONOate treatment altered CaMK signalling,
since phosphorylation of CaMKII (Thr
286) was unaltered
compared with non-stimulated (basal) muscle (Fig. 2e).
Abundance of the AMPK-α1 and AMPK-α2 subunits in
isolated skeletal muscle was unaltered after 1 h exposure of
isolated skeletal muscle to spermine NONOate or insulin
(Fig. 2a). In L6 cells, nitric oxide is known to increase
GLUT4 levels via an AMPK-dependent mechanism [16].
GLUT4 content was unaltered after 1 h exposure of isolated
skeletal muscle to spermine NONOate or insulin (data not
shown), suggesting spermine NONOate acutely increases
glucose transport in muscle by recruiting existing glucose
transporters to the cell surface, rather than through GLUT4
biogenesis.
Effect of spermine NONOate and insulin on glycogen
synthesis and glucose uptake To determine whether sper-
mine NONOate and insulin have an additive effect on
glucose metabolism, we measured glucose incorporation
into glycogen (glycogen synthesis) (Fig. 3a) and glucose
uptake (Fig. 3b) in L6 myotubes. Spermine NONOate and
insulin increased glycogen synthesis 1.2- (p<0.001) and
2.2-fold (p<0.0001), respectively (Fig. 3a). Combined
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Fig. 1 Effect of spermine nitric oxide donor on glucose transport,
cGMP content and AMPK activity in human skeletal muscle. Skeletal
muscle strips from seven healthy men were incubated in the absence
(basal) or presence of spermine NONOate (Spe-NO, nitric oxide
donor; 5 mmol/l) or insulin (120 nmol/l). Glucose transport (a),
intracellular cyclic GMP (cGMP) content (b), and both AMPK-α1( c)
and AMPK-α2( d) isoform-specific activity were determined. e
AMPK-α1 and AMPK-α2( f) isoform-specific activity in skeletal
muscle from healthy men (n=2) in response to acute exercise. Results
are expressed as mean ± SEM. *p<0.05, **p<0.01 vs basal
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Fig. 2 Effect of spermine nitric oxide donor on intracellular
signalling. Skeletal muscle strips from seven healthy participants were
incubated in the absence (basal) or presence of spermine NONOate
(Spe-NO, nitric oxide donor; 5 mmol/l) or insulin (120 nmol/l). a
Representative immunoblots of protein phosphorylation and abun-
dance. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Bar
graphs show quantification for (b) pAkt (Ser
473), (c) pTBC1D1/D4,
(d) pGSK3α/β (Ser
21/9) and (e) pCaMK II (Thr
286). Results (b–e) are
mean ± SEM arbitrary units. **p<0.01 vs basal
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effect on glycogen synthesis. Similarly, spermine NONOate
and insulin independently increased glucose uptake 1.2-
(p<0.01) and 1.2-fold (p<0.001) (Fig. 3b). Combined
exposure to spermine NONOate and insulin also had an
additive effect on glucose uptake. To delineate underlying
mechanism for the additive effect on glucose uptake and
metabolism, phosphorylation of AMPK, ACC, Akt and
TBC1D1/D4 was measured (Fig. 3c–f). Spermine NON-
Oate alone increased phosphorylation of AMPK Thr
172 6.3-
fold (p<0.05) and pACC Ser
227 1.7-fold (p<0.05), while
insulin alone had no effect. Interestingly, phosphorylation
of AMPK Thr
172 and pACC Ser
227 was unaltered in the
presence of spermine NONOate and insulin. Nevertheless,
insulin led to a 6.5-fold increase in Akt Ser
473 phosphor-
ylation (p<0.05) and a 3.5-fold increase in TBC1D1/D4
phosphorylation (p<0.05), these responses being unaltered
in presence of spermine NONOate. Finally, phosphoryla-
tion of Akt Ser
473 and TBC1D1/D4 was unaltered in the
presence of spermine NONOate.
Effect of the guanylate cyclase inhibitor LY-83583 on
spermine NONOate-induced glycogen synthesis and AMPK
phosphorylation An earlier report provides evidence that
LY-83583 inhibits guanylate cyclase activity [26]. Since
spermine NONOate exposure increased AMPK-α1-
associated activity in human skeletal muscle (Fig. 1c), as
well as phosphorylation of AMPK and ACC in L6
myotubes (Fig. 3c, e), we determined whether AMPK
activation lies downstream of cGMP. Treatment of L6
myotubes with spermine NONOate increased glycogen
synthesis and AMPK Thr
172phosphorylation, but these
responses were abolished in the presence of LY-83583
(10 µmol/l) (Fig. 4a, b). However, LY-83583 (10 µmol/l)
increased glycogen synthesis in L6 myotubes (p<0.001).
This dose was selected for our in vitro studies on the basis
of a previous report [10]. Treatment of L6 myotubes with a
lower concentration of LY-83583 (100 nmol/l) also
increased glycogen synthesis (data not shown). Importantly,
we provide evidence that only the α1 subunit of AMPK is
present in L6 myotubes, since immunoblot analysis failed
to detect the α2 subunit of AMPK (Fig. 4c).
Discussion
Regular exercise training improves glucose tolerance [27]
and skeletal muscle insulin sensitivity [28]i nt y p e2
diabetic patients, but the molecular mechanisms are
incompletely resolved. Although several strategies designed
to enhance compliance with physical activity regimens in
patients with insulin resistance have been proposed [29],
many type 2 diabetic patients rely on pharmacological
treatments to improve glucose homeostasis. Yet, these
current pharmacological treatments to enhance peripheral
insulin sensitivity have limited efficacy [30]. Therefore,
insight into novel mechanisms capable of enhancing
skeletal muscle glucose uptake could lead to new pharma-
ceutical strategies to improve treatment and possibly
prevent peripheral insulin resistance in patients with type
2 diabetes.
Nitric oxide signalling plays a key role in exercise/
contraction-induced metabolic responses in skeletal muscle
[1], partly via an AMPK-dependent mechanism [15].
During exercise/contraction, increased nitric oxide levels
are associated with induction of glucose uptake in skeletal
muscle [2–4]. Conversely, NOS inhibition reduces glucose
uptake during exercise in type 2 diabetic patients more than
in control participants [31]. Previous reports characterising
the direct effects of nitric oxide on glucose uptake are
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Fig. 3 Effect of spermine NONOate and insulin on glucose
metabolism and intracellular signalling in L6 myotubes. Myotubes
were treated with spermine NONOate (Spe-NO, nitric oxide donor;
20 µmol/l), in the absence (white bars) or presence (black bars) of
insulin. a Glucose incorporation into glycogen (n=13–15) and (b)
glucose uptake (n=10–15) were determined. Results are expressed as
mean ± SEM percentage of basal values. Signal transduction was also
determined for (c) pAMPK (Thr
172), (d) pAkt (Ser
473), (e) pACC
(Ser
227) and (f) pTBC1D1/D4 (n=5–7). Results are mean ± SEM
arbitrary units. *p<0.05, **p<0.01 (two-way ANOVA, followed by
Bonferroni post-test); ***p<0.001 (one-way ANOVA, followed by
Bonferroni post hoc test);
†p<0.0001 vs basal
Diabetologia (2010) 53:1142–1150 1147limited to in vitro studies of isolated rodent skeletal muscle
[9–11]. Here we provide evidence that pharmacological
treatment of human skeletal muscle with the nitric oxide
donor spermine NONOate increases glucose transport,
concomitant with increased cGMP levels and AMPK-α1-
associated activity. Using L6 myotubes (producing only the
α1-subunit of AMPK), we provide evidence that spermine
NONOate increases phosphorylation of AMPK and ACC,
with a concomitant increase in glucose transport and
glycogen synthesis. Our findings in human skeletal muscle
are compatible with earlier studies in rodent muscle
indicating that nitric oxide donors increase cGMP levels
and glucose transport [10]. Similar effects on glucose
transport stimulation were also observed in isolated rat
skeletal muscle exposed to the cGMP analogues 8-bromo-
cGMP [10] and dibutyryl cGMP [11]. The mechanism by
which cGMP regulates glucose uptake may involve two
enzymes, namely guanylate cyclase and phosphodiesterase,
but other mechanisms are also likely to be involved.
Inhibition of guanylate cyclase prevents the sodium
nitroprusside-induced increase in cGMP levels and glucose
transport [10]. Conversely, treatment of isolated skeletal
muscle with a phosphodiesterase inhibitor (Zaprinast)
increases cGMP levels, with a concomitant increase in
glucose uptake [32]. Collectively, these studies provide
evidence that the nitric oxide/cGMP pathway is likely to be
important in the regulation of glucose transport.
Nitric oxide signalling has been linked to AMPK
activation and glucose uptake [15, 16]. Here, we provide
evidence that in vitro exposure to a nitric oxide donor
increases glucose transport, with concomitant increase in
AMPK-α1-specific activity and AMPK-α1 phosphoryla-
tion in isolated human skeletal muscle and L6 myotubes.
Among the 12 possible AMPK heterotrimers, only three
(α1β2γ1, α2β2γ1, α2β2γ3) have been identified in
human skeletal muscle [33]. Each individual heterotrimer
is activated in a manner dependent on time and intensity
[34, 35], which may elicit signalling specificity in response
to a distinct set of stimuli. Our results in human skeletal
muscle and L6 myotubes provide evidence that nitric oxide
specifically increases AMPK-α1-associated activity and
AMPK-α1 phosphorylation respectively. Moreover in L6
myotubes, the guanylate cyclase enzyme inhibitor LY-
83583 prevents the nitric oxide donor-induced increase in
glycogen synthesis and α1-AMPK phosphorylation, pro-
viding evidence for a potential role of the AMPK-α1
subunit in the mechanism by which nitric oxide donors
increase glucose transport. These observations are consis-
tent with a previous study in rodent skeletal muscle [15],
which provided evidence that sodium nitroprusside
increases AMPK-α1-, but not AMPK-α2-associated activ-
ity. Furthermore, in rodent skeletal muscle, sodium
nitroprusside-induced increases in AMPK-isoform-specific
activity occurred independently of changes in ATP, creat-
inine phosphate or glycogen levels [15]. Thus, the nitric
oxide–cGMP pathway may be involved in the regulation of
AMPK-α1 activity and/or inhibition of the protein phos-
phatase responsible for AMPK regulation.
Although most Ampk (also known as Prkaa2) knockout
models provide evidence against a critical role for the
AMPK-α1 subunit in the regulation of skeletal muscle
glucose uptake [14], AMPK-α1 activation is required for
stimulation of glucose uptake in response to twitch
contraction [36]. Based on our results, the promotion of
glucose uptake effected by the nitric oxide donor appears to
be at least partly mediated via AMPK complexes contain-
ing the α1 subunit. However, the role of AMPK in nitric
oxide signalling is complex, since AMPK has also been
suggested to be an upstream kinase for NOS [17–19, 37].
Direct activation of AMPK, using 5′-aminoimidazole-4-
carboxamide ribonucleoside (AICAR), stimulates nitric
oxide production in human aortic endothelial cells [37]
and increases NOS activity in H-2K
b cells [17], implicating
a feedback loop between AMPK and NOS [16]. The
question of whether nitric oxide pathways lie upstream or
downstream of AMPK remains unresolved. For example,
AICAR-induced AMPK-activated glucose transport is
unaltered by NOS inhibition in isolated rat skeletal muscle
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Fig. 4 Effect of the guanylate cyclase inhibitor LY-83583 on
spermine NONOate induced-glycogen synthesis and AMPK phos-
phorylation. L6 myotubes were treated with spermine NONOate (Spe-
NO, nitric oxide donor; 20 µmol/l) and incubated in the absence or
presence of LY-835883 (10 µmol/l). Glycogen synthesis (n=5–8) (a)
and AMPK Thr
172 phosphorylation (n=5–6) (b) were determined.
Results are reported as mean ± SEM. Glucose incorporation into
glycogen is expressed as percentage of basal. c Protein content of the
AMPK-α1 and AMPK-α2 subunits was determined in L6 myotubes.
***p<0.001 vs basal
1148 Diabetologia (2010) 53:1142–1150[38]. The direct interaction between the nitric oxide/cGMP
pathway and AMPK warrant further investigation.
To determine the intracellular mechanism by which the
nitric oxide donor spermine NONOate increases glucose
transport, components of the canonical insulin signalling
cascade were assessed. The Akt- and Rev/Rex activation
domain-binding protein (Rab) GTPase-activating proteins,
TBC1D1 and TBC1D4, are the most distal signalling
proteins implicated in GLUT4 translocation [39, 40]. In
human skeletal muscle, insulin exposure led to an expected
increase in phosphorylation of Akt, TBC1D1/D4 (detected
using a PAS antibody) and GSK3, while exposure to the
nitric oxide donor had no effect. These data indicate that
nitric oxide-stimulated glucose transport is mediated via an
insulin-independent pathway. Nitric oxide has also been
linked as a positive [16] modulator of GLUT4 production.
However, GLUT4 protein content was unaltered in
response to spermine NONOate (data not shown), presum-
ably because of the shorter incubation time and low
concentration of the nitric oxide donor used in this study.
CaMKII signalling has been implicated in the mechanism
by which muscle contraction increases glucose uptake [13].
Nevertheless, CaMKII phosphorylation was unaltered in
response to insulin or spermine NONOate. In contrast to
our results for AMPK signalling, insulin and CaMKII
signalling do not appear to play a role in nitric oxide action
on skeletal muscle glucose transport. In L6 myotubes, the
nitric oxide donor and insulin had an additive effect on
glycogen synthesis and glucose uptake without further
increase in insulin-induced Akt and TBC1D1/D4 phos-
phorylation. These results suggest that nitric oxide pro-
motes glucose uptake by an insulin-independent
mechanism. Furthermore, the stimulatory effect of the nitric
oxide donor on AMPK and ACC phosphorylation under
insulin-stimulated conditions was prevented, excluding a
role for AMPK signalling in the additive effect on glycogen
synthesis and glucose uptake.
In summary, the nitric oxide donor spermine NONOate
increases cGMP levels and promotes glucose transport,
concomitantly with AMPK-α1-isoform-specific activation
in human skeletal muscle. Further study to delineate
mechanisms and the therapeutic window is warranted.
Spermine NONOate also increased glucose transport in
L6 myotubes, concomitantly with an increase in AMPK-
α1-isoform-specific phosphorylation. Moreover, these
effects were prevented in presence of a guanylate cyclase
inhibitor. Further studies on the mechanisms by which
AMPK-α1-isoform-specific signalling is directly linked to
nitric oxide action are warranted. Taken together with
recent evidence showing that sodium nitroprusside in-
creased glucose uptake in human primary myotubes derived
from healthy volunteers and patients with type 2 diabetes
[41], our findings have clear clinical implications, since
manipulation of the nitric oxide/cGMP signalling cascade
could enhance glucose uptake by an insulin-independent
mechanism to potentially improve whole-body glucose
homeostasis in type 2 diabetic patients.
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